Authors
Latest:
Dr. Sharma on Optimal Systemic Therapy for Early-Stage TNBCPriyanka Sharma, MD, discusses updates in optimal systemic therapy strategies in early-stage triple-negative breast cancer.
Latest:
Dr. Francis on Ovarian Suppression in Young Women With Breast CancerPrudence Francis, MD, Peter MacCallum Cancer Centre, discusses ovarian suppression in young women with hormone receptor (HR)-positive breast cancer.
Latest:
Dr. Twardowski on Steps Toward Optimal Sequencing for mCRPC TherapiesPrzemyslaw W. Twardowski, MD, director, Prostate Oncology Strategic Program, director, Genitourinary Program, clinical professor, Department of Medical Oncology and Therapeutics Research, discusses the necessary steps toward determining optimal sequencing of treatments for patients with metastatic castration-resistant prostate cancer.
Latest:
Dr. Iyengar on the Rationale Behind Hypofractionated Radiation in NSCLCPuneeth Iyengar, MD, radiation oncologist, University of Texas Southwestern Medical Center, discusses the rationale behind the use of hypofractionated radiation as a treatment for patients with non–small cell lung cancer.
Latest:
Robot-Assisted Cystectomy Is Feasible for Many Patients With Bladder CancerTo determine the 10-year oncologic outcomes and recurrence patterns after robot-assisted radical cystectomy, a group within the Department of Urology at Roswell Park Comprehensive Cancer Center performed a retrospective review.
Latest:
Radiotherapy in the Modern Era in the Management of Langerhans Cell HistiocytosisIntensity-modulated radiotherapy reduces the mean radiation dose delivered to critical normal structures and should be considered in Langerhans cell histiocytosis treatment when radiotherapy is indicated, particularly given the expected, long-term survival of these patients.
Latest:
Dr. Chu Discusses CNS Penetration of CeritinibQuincy Chu, MD, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, discusses the ability of ceritinib to penetrate the CNS.
Latest:
Dr. Kelley on Newly Approved Agents in HCCR. Kate Kelley, MD, associate professor of clinical medicine, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the clinical impact of REFLECT and CELESTIAL in hepatocellular carcinoma (HCC).
Latest:
Dr Kelley on the Need for Additional Second-line Therapies in CholangiocarcinomaR. Kate (Katie) Kelley, MD, discusses unmet needs and treatment challenges within the current standard-of-care for patients with cholangiocarcinoma.
Latest:
Perspectives on Treating CCA Moving ForwardA panel of GI oncologists share their thoughts on the future of using precision medicine to treat patients with bile duct cancers.
Latest:
Cholangiocarcinoma: Potential Therapies Under InvestigationAn overview of various treatment opportunities under study that are looking at using novel techniques to help personalize treatment for patients with bile duct cancers.
Latest:
Dr Randall on the Effect of Socioeconomic Factors in Pediatric Nonmetastatic OsteosarcomaR. Lor Randall, MD, FACS, discusses the impact of race, ethnicity, and socioeconomic factors on outcomes in pediatric patients with nonmetastatic osteosarcoma.
Latest:
Dr. Paulson on the Importance of Biomarker Testing in OncologyR. Steven Paulson, MD, discusses the importance of molecular testing in the era of precision medicine in oncology.
Latest:
Dr Naumann on the Changing Treatment Landscape in Cervical CancerR. Wendel Naumann, MD, FACOG, FACS, discusses how the evolution of immunotherapy has changed the treatment landscape for patients with recurrent or metastatic cervical cancer.
Latest:
Emerging Treatments for MyelofibrosisAndrew Kuykendall, MD, and Raajit K. Rampal, MD, PhD, conclude that the increasing complexity in myelofibrosis treatment options, including multiple JAK inhibitors and emerging combination therapies, signals an exciting era of individualized care, yet underscores the need for reevaluating study end points to enhance patient outcomes further.
Latest:
Dr. Freedman Discusses Dual HER2-Targeted Therapy in Breast CancerRachel A. Freedman, MD, MPH, associate clinical director, Breast Oncology Center, Susan F. Smith Center for Women's Cancers, Dana-Farber Cancer Institute, senior physician, assistant professor of medicine, Harvard Medical School, discusses dual HER2-targeted therapies in breast cancer.
Latest:
Dr. Grossman Discusses TTFields for GlioblastomaRachel Grossman, MD, Neurosurgery Department, Tel Aviv Sourasky Medical Center, discusses tumor treating fields for the treatment of patients with glioblastoma.
Latest:
Dr. Grisham on the Combination of VS-6766 With Defactinib in Ovarian CancerRachel N. Grisham, MD, discusses the rationale to explore the combination of VS-6766 and defactinib in patients with low-grade serous ovarian cancer.
Latest:
Brexucabtagene Autoleucel Provides New Option for Patients With R/R MCLBrexucabtagene autoleucel induced durable response in patients with relapsed/refractory mantle cell lymphoma, according to findings from the phase 2 ZUMA-2 trial, leading to an FDA approval for use in this patient population on July 24, 2020.
Latest:
Palliative Care Issues in Gynecologic CancerPalliative care should address the unique symptom profile of gynecologic cancer and be tailored to individual socioeconomic environments.
